ZNC 2381

Drug Profile

ZNC 2381

Latest Information Update: 06 Jul 2001

Price : $50

At a glance

  • Originator Zeria
  • Developer Nippon Chemiphar; Zeria
  • Class Hepatoprotectants
  • Mechanism of Action Cytokine inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Liver disorders

Most Recent Events

  • 06 Jul 2001 Discontinued-Preclinical for Liver disorders in Japan (Unknown route)
  • 21 Jul 2000 A preclinical study has been added to the Liver Disorders pharmacodynamics section
  • 21 Jul 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top